Vismodegib and the hedgehog pathway inhibitors: A historical perspective to current clinical application

Jennifer C. Tang, C. William Hanke, Ivor Caro

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Vismodegib (Erivedge, Genentech-Roche) is the first in class of Hedgehog pathway inhibitors approved for treatment of metastatic basal cell carcinoma (BCC), or locally advanced BCC that has recurred after surgery or is not amenable to surgery or radiation. Its path to discovery has been unique and traces its origin to corn lilies, sheep, Drosophila flies, and the Hedgehog signaling pathway.

Original languageEnglish (US)
Pages (from-to)506-508
Number of pages3
JournalJournal of Drugs in Dermatology
Volume17
Issue number5
StatePublished - May 2018
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Vismodegib and the hedgehog pathway inhibitors: A historical perspective to current clinical application'. Together they form a unique fingerprint.

Cite this